PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 40

FDA Immunization 40

PharmaShots

FEBRUARY 17, 2023

Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)

FDA 40

FDA Vaccines 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

pharmaphorum

NOVEMBER 19, 2020

Because Roche has never applied for Avastin to be used in wet AMD, clinics in the US have had to choose between the peace of mind offered by the regulatory process and Lucentis’ higher price tag, or the unapproved off-label formulation of Avastin at a lower price.

FDA 64

FDA Labelling 64

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. Their widespread agreements are established in the UK, followed by seven additional countries (Australia, France, Netherlands, Spain, Poland, Italy, and Canada). million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

FDA 105

FDA 105

pharmaphorum

JUNE 15, 2021

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. He is a member of Accenture’s Global Management Committee.

Vaccines 90

Vaccines 90

Policy Prescription

APRIL 1, 2022

I know of no other counterfeit drug breach in Canada or the European Union of this magnitude. . wholesale pharmacy industry against allowing the importation of more affordable medicine from Canada, which they insinuate means more counterfeit drugs. In 2018, CanadaDrugs, Ltd.

FDA 40

FDA Documentation 40

Pharmaceutical Technology

MARCH 17, 2023

In some cases, she said, “[drug] innovation would have been otherwise hindered by their price tag alone”. Watt explained that for newer, first-in-class drugs these types of agreements can also give healthcare systems safety in their decisions to approve certain drugs. Click here to watch this webinar and access the presentation.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Novo Nordisk is another company leading the charge in this field. In a Phase II study, CagriSema achieved a numerically higher body weight reduction of 15.6% compared to a 5.1%

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Novo Nordisk is another company leading the charge in this field. In a Phase II study, CagriSema achieved a numerically higher body weight reduction of 15.6% compared to a 5.1%

Insurance 98

Insurance Labelling Communication FDA 98